Navigation Links
Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain
Date:1/4/2008

ontinuous, long-term analgesia at the site of a surgical wound.

Innocoll has recently completed a phase 2 clinical trial in patients undergoing hysterectomy surgery in the absence of gynecological cancers at Wexham Park Hospital, Slough, UK. The results of this trial were particularly encouraging, showing evidence of sustained, post-operative analgesia for approximately 96 hours as measured by VAS (visual analogue scale) scores and reduced dependence on systemic morphine administered by PCA (patient- controlled analgesia). This extended action was achieved despite a low total bupivacaine dose (150mg as the hydrochloride salt), which is well below the allowable daily dose and equivalent to that used by some practitioners for a once-off wound infiltration with bupivacaine solution prior to wound closure.

For the planned series of phase 2 multi-centered, controlled clinical trials to be performed in the US, Innocoll has appointed Premier Research Group, a recognized industry leader in clinical research for acute and chronic pain, to co-ordinate up to five trials in a variety of soft and hard tissue procedures; including hysterectomy, herniorrhaphy, open gastrointestinal surgery and orthopedic surgery. The first of these trials that has commenced dosing will compare the analgesic effect of BUPIVACAINE SURGICAL IMPLANT versus a placebo implant and current standard of care in patients undergoing abdominal hysterectomy at eight different US sites. The other phase 2 soft tissue trials in herniorrhaphy and open gastrointestinal surgeries are expected to commence in early 2008.

About one third of women in the US have a hysterectomy by age 60 and each year, more than 600,000 hysterectomies are performed across the country. Other procedures where the product could potentially be used routinely include caesarean section, inguinal hernia repair, open-heart surgery, mastectomy, open gastrointestinal surgery, cholecystectomy, vascular surgery, and various ortho
'/>"/>

SOURCE Innocoll Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Innocoll Provides a Progress Update on its Clinical Development Programs and Specialty Pharmaceutical Operations
2. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Mildly Infected Diabetic Foot Ulcers
3. Innocoll Announces Dosing of First Patient in US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections in Cardiac Surgery Patients
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
6. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
7. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
8. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
9. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
10. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
11. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... August 3, 2015 Shire ... today that it has acquired New ... for $300 million. With the acquisition, Shire acquires ... combining 0.6% povidone iodine (PVP-I) and 0.1% dexamethasone), ... of infectious conjunctivitis, an ocular surface condition commonly ...
(Date:8/2/2015)... , Aug. 3, 2015  Lexicon Pharmaceuticals, ... the pivotal TELESTAR Phase 3 clinical trial met ... telotristat etiprate in treating cancer patients with carcinoid ... current standard of care. Telotristat etiprate was discovered ... technology, and is the company,s first discovery to ...
(Date:7/31/2015)... -- More than 1,500 substance abuse prevention and treatment ... Indianapolis Aug. 2-6 for Community Anti-Drug ... . The week-long training, held at the JW Marriott, ... nation,s biggest public health challenges – youth drug use. ... one-of-a-kind intensive training opportunity, offering more than 70 half-day ...
Breaking Medicine Technology:Shire Acquires Privately Held Foresight Biotherapeutics Inc., Boosting Ophthalmics Portfolio with Late-Stage Asset 2Shire Acquires Privately Held Foresight Biotherapeutics Inc., Boosting Ophthalmics Portfolio with Late-Stage Asset 3Shire Acquires Privately Held Foresight Biotherapeutics Inc., Boosting Ophthalmics Portfolio with Late-Stage Asset 4Shire Acquires Privately Held Foresight Biotherapeutics Inc., Boosting Ophthalmics Portfolio with Late-Stage Asset 5Shire Acquires Privately Held Foresight Biotherapeutics Inc., Boosting Ophthalmics Portfolio with Late-Stage Asset 6Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 2Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 3Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 4Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 5Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 6Community Leaders From Across The Country Head To Indianapolis For CADCA 2015 Mid-Year Training Institute Aug. 2-6 2
... Medical AB ( http://www.omxgroup.com, OMX: DIAM B; ... http://www.otcqx.com, OTC: ... B)(OTC: DMYDY)announced today that the Swedish Medical Products,Agency (MPA) has ... therapeutic diabetes vaccine Diamyd(R)., (Logo: http://www.newscom.com/cgi-bin/prnh/20080314/297194 ), ...
... Onset with SYMBICORT with Improved Lung Function within ... ... WILMINGTON, Del., March 18 Data from a new,study demonstrated ... greater,and faster bronchodilatory effects, or opening of the airways, compared,with ...
Cached Medicine Technology:Diamyd(R) Diabetes Vaccine Receives Approval to Start Phase III Trials in Europe 2Study Compares Bronchodilatory Effects of SYMBICORT(R) and Advair in Adults With Asthma 2Study Compares Bronchodilatory Effects of SYMBICORT(R) and Advair in Adults With Asthma 3Study Compares Bronchodilatory Effects of SYMBICORT(R) and Advair in Adults With Asthma 4
(Date:8/3/2015)... Pass, OR (PRWEB) , ... August 03, 2015 ... ... Northeast California’s Modoc National Forest, to Ahjumawi Lava Springs, California’s northernmost and among ... of California’s largest untapped ground water aquifers, whose main outflow is at Ahjumawi ...
(Date:8/3/2015)... ... August 03, 2015 , ... From 2006-2017 the number ... according to market research compiled for the National Association of Dental Laboratories ( ... Labor, Bureau of Labor Statistics. As the number of dental laboratories decreases, dentists ...
(Date:8/3/2015)... ... 2015 , ... Constantin Vasilica, 48 from Romania wanted to have an alternative ... many years of suffering and using medications with strong side effects. This had already ... extra time off or wait longer hours in the waiting rooms. Instead, he went ...
(Date:8/3/2015)... ... 03, 2015 , ... The American Institute of Architects ... to collaborate across a wide range of initiatives ranging from code development and ... , “Our combined membership, consisting of practicing design professionals, code officials, and the ...
(Date:8/2/2015)... ... August 03, 2015 , ... A new Phase I research study is ... study is led by Kenneth G. Lucas, M.D. , chief of the division ... with colleagues at Kosair Children’s Hospital and in the UofL Department ...
Breaking Medicine News(10 mins):Health News:Medicine Lake Aquifer could ease California drought says fresh water advocate Sharon Kleyne – but is this necessary? 2Health News:Medicine Lake Aquifer could ease California drought says fresh water advocate Sharon Kleyne – but is this necessary? 3Health News:Medicine Lake Aquifer could ease California drought says fresh water advocate Sharon Kleyne – but is this necessary? 4Health News:Dental Association Announces Impending Reduction of Dental Laboratories Could Impact Dentists 2Health News:Dental Association Announces Impending Reduction of Dental Laboratories Could Impact Dentists 3Health News:Chinese Health Care Provider Heshoutang Now Give Patients Complimentary Online Healing Options 2Health News:Chinese Health Care Provider Heshoutang Now Give Patients Complimentary Online Healing Options 3Health News:Architects, International Code Council Ink Five-Year Collaborative Agreement 2Health News:Architects, International Code Council Ink Five-Year Collaborative Agreement 3Health News:UofL Physicians Conducting Vaccine Trial for Children with Relapsed Tumors at Kosair Children’s Hospital 2
... Exposition Park LOS ANGELES, ... March of Dimes premier fundraising event that benefits all babies--those ... thrive. 11,000 walkers are expected at this largest March for ... Exposition Park, at the corner of S. Figueroa and 39th ...
... associations representing the state,s 114 hospitals have reached a ... 2010.Among other principles, the groups urged the state to ... agreed on a minimum floor that all hospitals should ... shared today with members of the state Legislature by ...
... Saturday, April 25 from 9 a.m. until noon, ... (NAMI-OC) will bring together speakers, agencies and service ... Front Line conferences provide important information on PTSD ... and suicide prevention. The conference is designed not ...
... The National Medical Association (NMA), the nation,s premier ... funding in the amount of $120,000 from the ... of a three-year grant commitment, designed "to promote ... sustaining collaboration among partner organizations."Partner organizations for this ...
... favors people in urban areas , , TUESDAY, April 21 (HealthDay ... or remote areas are not less likely to get a ... finds. , Researchers analyzed U.S. data on 699,751 adults ... list between 1995 and 2007. After about two years on ...
... Patients who drank before diagnosis had reduced risk of ... (HealthDay News) -- Patients with non-Hodgkin lymphoma who drank ... risk of relapse or death, according to a study ... researchers looked at more than 500 women with non-Hodgkin ...
Cached Medicine News:Health News:Farmers Insurance Joins March of Dimes March for Babies April 25, 2009 2Health News:Hospital Groups Stand United on State Budget 2Health News:Hospital Groups Stand United on State Budget 3Health News:Hospital Groups Stand United on State Budget 4Health News:National Medical Association Receives Funding From Kellogg for Training Community Advocates 2Health News:Distance No Bar to Kidney Transplants in Remote Areas 2Health News:Wine May Guard Against Lymphoma Recurrence 2
... Microscope with excellent maneuverability. Konan ... weight maintaining high quality. Easy ... by simply changing the adapter. ... has resulted in a sharp ...
To maintain the conjunctival cul-de-sacs after enucleation or evisceration without hindering lid closure....
With side bite Instrument recommended to catch the polypropylene thread in the nose....
Instrument necessary for insertion of Ritleng Bicanaliculus systems and of Self-Threading Monoka systems....
Medicine Products: